Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).

Head and neck cancer Nivolumab

Journal

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

ISSN: 1434-4726

Titre abrégé: Eur Arch Otorhinolaryngol

Pays: Germany

ID NLM: 9002937

Informations de publication

Date de publication:
25 May 2024

Historique:

received: 13 11 2023

accepted: 16 05 2024

medline: 25 5 2024

pubmed: 25 5 2024

entrez: 25 5 2024

Statut: aheadofprint

Résumé

Head and neck cancers (HNCs) represent a significant global health concern due to high morbidity and mortality rates. Despite therapeutic advances, the prognosis for advanced or recurrent cases remains challenging. Nivolumab obtained approval for recurrent or metastatic HNC based on the Phase III CheckMate 141 trial. This study aimed to evaluate the real-world outcomes of nivolumab in patients with non-nasopharyngeal HNC. In this multicenter retrospective study, we analyzed 124 patients with recurrent or metastatic non-nasopharyngeal HNC who received nivolumab in the second-line setting and beyond. Data were collected from 20 different cancer centers across Turkey. The effectiveness and safety of the treatment and survival outcomes were evaluated. Nivolumab exhibited favorable clinical responses, yielding an objective response rate of 29.9% and a disease control rate of 55.7%. Safety assessments revealed a generally well-tolerated profile, with no instances of treatment discontinuation or mortality due to side effects. Survival analysis disclosed a median overall survival (OS) of 11.8 (95% CI 8.4-15.2) months. Multivariate analysis revealed that ECOG-PS ≥ 1 (HR: 1.64, p = 0.045), laryngeal location (HR: 0.531, p = 0.024), and neutrophil-to-lymphocyte ratio > 3.5 (HR: 1.97, p = 0.007) were independent predictors of OS. Nivolumab is an effective and safe treatment option for patients with recurrent or metastatic non-nasopharyngeal HNC in real-world settings. Further studies are needed on factors affecting response to treatment and survival outcomes.

Identifiants

DOI: 10.1007/s00405-024-08744-4 PMID: 38795147

pubmed: 38795147

doi: 10.1007/s00405-024-08744-4

pii: 10.1007/s00405-024-08744-4

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

doi: 10.3322/caac.21492 pubmed: 30207593

Fitzmaurice C, Allen C, Barber RM et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 3(4):524–548

doi: 10.1001/jamaoncol.2016.5688 pubmed: 27918777

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics. CA Cancer J Clin 68(1):7–30

doi: 10.3322/caac.21442 pubmed: 29313949

Chow LQM (2020) Head and Neck Cancer. N Engl J Med 382(1):60–72

doi: 10.1056/NEJMra1715715 pubmed: 31893516

Vermorken JB, Specenier P (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21(Suppl 7):vii252–vii261

doi: 10.1093/annonc/mdq453 pubmed: 20943624

Marur S, Forastiere AA (2008) Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83(4):489–501

doi: 10.4065/83.4.489 pubmed: 18380996

Pisani P, Airoldi M, Allais A et al (2020) Metastatic disease in head & neck oncology. Acta Otorhinolaryngol Ital 40(Suppl. 1):S1-s86

doi: 10.14639/0392-100X-suppl.1-40-2020 pubmed: 32469009 pmcid: 7263073

Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867

doi: 10.1056/NEJMoa1602252 pubmed: 27718784 pmcid: 5564292

Cohen EEW, Bell RB, Bifulco CB et al (2019) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 7(1):184

doi: 10.1186/s40425-019-0662-5 pubmed: 31307547 pmcid: 6632213

Yasumatsu R, Shimizu Y, Hanai N et al (2022) Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study. Int J Clin Oncol 27(1):95–104

doi: 10.1007/s10147-021-02047-y pubmed: 34773525

Vasiliadou I, Breik O, Baker H et al (2021) Safety and treatment outcomes of nivolumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: retrospective multicenter cohort study. Cancers (Basel) 13(6):1413

doi: 10.3390/cancers13061413 pubmed: 33808781

Matsuki T, Okamoto I, Fushimi C et al (2020) Real-world, long-term outcomes of nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck and impact of the magnitude of best overall response: a retrospective multicenter study of 88 patients. Cancers (Basel) 12(11):3427

doi: 10.3390/cancers12113427 pubmed: 33218183

Wagner SM, Magnes T, Melchardt T et al (2023) Real-world data of palliative first-line checkpoint inhibitor therapy for head and neck cancer. Anticancer Res 43(3):1273–1282

doi: 10.21873/anticanres.16274 pubmed: 36854497

Gogate A, Bennett B, Poonja Z et al (2023) Phase 4 multinational multicenter retrospective and prospective real-world study of nivolumab in recurrent and metastatic squamous cell carcinoma of the head and neck. Cancers (Basel) 15(14):3552

doi: 10.3390/cancers15143552 pubmed: 37509217

Kariya S, Shimizu Y, Hanai N et al (2021) Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. Int J Clin Oncol 26(6):1049–1056

doi: 10.1007/s10147-021-01900-4 pubmed: 33830342 pmcid: 8134300

Serindere G, Bolgul B, Gursoy D, Hakverdi S, Savas N (2019) Comparison of head and neck cancer distribution in Turkish and Syrian populations. Iran J Public Health 48(10):1810–1816

pubmed: 31850258 pmcid: 6908918

Guo K, Xiao W, Chen X, Zhao Z, Lin Y, Chen G (2021) Epidemiological trends of head and neck cancer: a population-based study. Biomed Res Int 2021:1738932

pubmed: 34337000 pmcid: 8294963

Ferris RL, Blumenschein G, Fayette J et al (2018) Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45–51

doi: 10.1016/j.oraloncology.2018.04.008 pubmed: 29884413 pmcid: 6563923

Okamoto I, Sato H, Kondo T et al (2019) Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study. Acta Otolaryngol 139(10):918–925

doi: 10.1080/00016489.2019.1648867 pubmed: 31460818

Matsuo M, Yasumatsu R, Masuda M et al (2020) Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol 101:104525

doi: 10.1016/j.oraloncology.2019.104525 pubmed: 31863963

Hori R, Shinohara S, Kojima T et al (2019) Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma. Cancers (Basel) 11(9):1317

doi: 10.3390/cancers11091317 pubmed: 31500103

Otsuki S, Hori R, Shinohara S et al (2022) Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Auris Nasus Larynx 49(5):834–844

doi: 10.1016/j.anl.2022.02.006 pubmed: 35232636

Kim H, Kwon M, Kim B et al (2020) Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. BMC Cancer 20(1):727

doi: 10.1186/s12885-020-07214-4 pubmed: 32758163 pmcid: 7405432

Vallianou NG, Evangelopoulos A, Kounatidis D et al (2023) Immunotherapy in head and neck cancer: where do we stand? Curr Oncol Rep 25(8):897–912

doi: 10.1007/s11912-023-01425-1 pubmed: 37213060

Hwang M, Canzoniero JV, Rosner S et al (2022) Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer 10(6):e004688

doi: 10.1136/jitc-2022-004688 pubmed: 35688557 pmcid: 9189831

Valero C, Lee M, Hoen D et al (2021) Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 12(1):729

doi: 10.1038/s41467-021-20935-9 pubmed: 33526794 pmcid: 7851155

Cao D, Xu H, Xu X, Guo T, Ge W (2018) A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies. Oncoimmunology 7(11):e1507262

doi: 10.1080/2162402X.2018.1507262 pubmed: 30377569 pmcid: 6205035

Nakaya A, Kurata T, Yoshioka H et al (2018) Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol 23(4):634–640

doi: 10.1007/s10147-018-1250-2 pubmed: 29442281 pmcid: 6097082